Gregory Dardas, MD
Neurology · Auburn, MINPI 1750350096
Payments from drug & device makers
Across 379 payments — averaging $15.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$2K
- AbbVie$847
- Novartis$419
- Bristol Myers Squibb$399
- UCB, Inc.$245
- Eisai Inc.$230
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$220%
- Food & beverage$5,68999%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 162 | $1,541 |
| AbbVie(2 entities) | 41 | $847 |
| Novartis | 24 | $419 |
| Bristol Myers Squibb | 21 | $399 |
| UCB, Inc. | 13 | $245 |
| Eisai Inc. | 11 | $230 |
| Lilly USA, LLC | 10 | $192 |
| Neurocrine Biosciences, Inc. | 10 | $182 |
| Genentech USA, Inc. | 9 | $162 |
| Teva Pharmaceuticals USA, Inc. | 9 | $157 |
| Supernus Pharmaceuticals, Inc. | 7 | $143 |
| Amgen | 9 | $131 |
| Neurelis, Inc. | 4 | $130 |
| EMD Serono, Inc. | 6 | $109 |
| Otsuka America Pharmaceutical, Inc. | 5 | $99 |
| Biohaven Pharmaceuticals, Inc. | 3 | $96 |
| Kyowa Kirin, Inc. | 4 | $75 |
| Sanofi | 3 | $46 |
| Acadia Pharmaceuticals Inc | 3 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $42 |
| Corium, LLC | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 2 | $39 |
| Adamas Pharmaceuticals, Inc. | 2 | $38 |
| Avion Pharmaceuticals | 2 | $36 |
| Harmony Biosciences LLC | 1 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $31 |
| Tanabe Pharma America, Inc. | 1 | $26 |
| Acorda Therapeutics, Inc | 1 | $22 |
| Pfizer | 1 | $21 |
| Argenx US, Inc. | 1 | $20 |
| Upsher-smith Laboratories LLC | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Impel Pharmaceuticals Inc. | 1 | $15 |
| AstraZeneca | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
How this compares
$5,718 in reported general payments places this provider in the 65th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZeposiaOzanimod Hydrochloride | 14 | $162,258 |
| AustedoDeutetrabenazine | 21 | $110,994 |
| TecfideraDimethyl Fumarate | 11 | $105,855 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $82,479 |
| CopaxoneGlatiramer Acetate | 13 | $81,539 |
| Nurtec OdtRimegepant Sulfate | 45 | $52,667 |
| NeuproRotigotine | 28 | $49,407 |
| Aimovig AutoinjectorErenumab-Aooe | 57 | $45,657 |
| Glatiramer Acetate | 16 | $36,147 |
| Emgality PenGalcanezumab-Gnlm | 29 | $20,091 |
| UbrelvyUbrogepant | 18 | $18,791 |
| FingolimodFingolimod Hcl | 17 | $13,845 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 264 | $11,251 |
| Dimethyl Fumarate | 11 | $7,603 |
| Rivastigmine | 19 | $6,031 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Copaxone | $157 | $192,53334 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $43 | $162,25814 claims |
| BiogenTecfidera | $1,541 | $105,85511 claims |
| PfizerNurtec Odt, Dilantin | $21 | $57,49270 claims |
| UCB, Inc.Neupro | $245 | $49,40728 claims |
| AbbVieUbrelvy | $847 | $18,79118 claims |
| Upsher-smith Laboratories LLCTopiramate | $19 | $81640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 652 neurology providers in Michigan.
Other neurology in Auburn
- Aaron EllenbogenFarmington Hills$14.5M
- Martin BelkinFarmington Hills$5.8M
- Evanthia BernitsasDetroit$4.8M
- Yang Mao DraayerFarmington Hills$4.2M
- Mirela CerghetDetroit$3.8M
- Peter le WittWest Bloomfield$3.2M
- Judith HeidebrinkAnn Arbor$2.2M
- Denise LeungAnn Arbor$2M
- Rany AburashedOwosso$1.9M
- Jeanie CoteOwosso$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.